Intensity Therapeutics Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
INTS
- Share Price
-
$3.08
- (As of Friday Closing)
Intensity Therapeutics General Information
Description
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Contact Information
Website
www.intensitytherapeutics.comCorporate Office
- 1 Enterprise Drive
- Suite 430
- Shelton, CT 06484-4779
- United States
Corporate Office
- 1 Enterprise Drive
- Suite 430
- Shelton, CT 06484-4779
- United States
Intensity Therapeutics Timeline
Intensity Therapeutics Stock Performance
As of 13-Nov-2026, Intensity Therapeutics’s stock price is $3.08. Its current market cap is $10.2M with 3.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.08 | $3.10 | $2.80 - $15.00 | $10.2M | 3.3M | 22.9K | -$3.44 |
Intensity Therapeutics Financials Summary
As of 30-Sep-2026, Intensity Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,569 | 17,690 | 23,947 | 101,996 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (12,377) | (11,786) | (16,582) | (10,557) |
| Net Income | (12,036) | (11,606) | (16,268) | (10,538) |
| Total Assets | 10,287 | 14,101 | 4,783 | 17,295 |
| Total Debt | 87 | 110 | 138 | 158 |
Intensity Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Intensity Therapeutics Comparisons
Industry
Financing
Details
Intensity Therapeutics Competitors (56)
One of Intensity Therapeutics’s 56 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| ALX Oncology | Formerly VC-backed | South San Francisco, CA | ||||
| Zymeworks | Formerly VC-backed | Vancouver, Canada | ||||
| Replimune | Formerly VC-backed | Woburn, MA | ||||
| PhaseBio Pharmaceuticals | Formerly VC-backed | Malvern, PA |
Intensity Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Intensity Therapeutics Patents
Intensity Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-3125942-A1 | Breeding slats | Active | 04-Aug-2021 | ||
| FR-3125942-B1 | Livestock slats | Active | 04-Aug-2021 | ||
| ES-2813340-T3 | Cancer treatment method | Active | 21-Sep-2012 | ||
| JP-2015533809-A | How to treat cancer | Active | 21-Sep-2012 | ||
| JP-6374388-B2 | How to treat cancer | Active | 21-Sep-2012 | A61K47/14 |
Intensity Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Intensity Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.23 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Intensity Therapeutics FAQs
-
When was Intensity Therapeutics founded?
Intensity Therapeutics was founded in 2012.
-
Where is Intensity Therapeutics headquartered?
Intensity Therapeutics is headquartered in Shelton, CT.
-
What is the size of Intensity Therapeutics?
Intensity Therapeutics has 7 total employees.
-
What industry is Intensity Therapeutics in?
Intensity Therapeutics’s primary industry is Drug Delivery.
-
Is Intensity Therapeutics a private or public company?
Intensity Therapeutics is a Public company.
-
What is Intensity Therapeutics’s stock symbol?
The ticker symbol for Intensity Therapeutics is INTS.
-
What is the current stock price of Intensity Therapeutics?
As of 13-Nov-2026 the stock price of Intensity Therapeutics is $3.08.
-
What is the current market cap of Intensity Therapeutics?
The current market capitalization of Intensity Therapeutics is $10.2M.
-
Who are Intensity Therapeutics’s competitors?
Aura Biosciences, ALX Oncology, Zymeworks, Replimune, and PhaseBio Pharmaceuticals are some of the 56 competitors of Intensity Therapeutics.
-
What is Intensity Therapeutics’s annual earnings per share (EPS)?
Intensity Therapeutics’s EPS for 12 months was -$3.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
